Collaborative Organization for RehothRX Evaluation Investigators.
| < back
The trial evaluated effects of RheothRx (poloxame188) in patients acute myocardial infarction. The trial demonstrated that RheothRx had no effect on mortality, reinfarction, cardiogenic shock and an adverse effect on renal function, LV ejection fraction and heart failure (especially at higher doses). Based on result sof this trial further development of the study drug was discontinued. The early rapid provision of clear results resulted in clear decisions, so that a larger phase III trial was not needed.
Study of Design: Open-Label placebo-controlled close-finding trial.
Intervention: RehothRX vs. Placebo.
Length of Study: 1.5 years
# of Patients: 2,948
Patient Populations: Acute ST segment elevation myocardial infarction.
Not available at this time.
Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)
Collaborative Organization for RheothRx Evaluation (CORE) Investigators. Effects of RheothRx on mortality, morbidity, left ventricular function and infarct size in patients with acute myocardial infarction. Circulation 1997;96:192-201.